Cormorant Asset Management LP's Q3 2026 13F: 13 new positions, 3 exits
Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 60 reported positions · accession 0001583977-26-000011
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| New | BLOSSOMHILL THERAPEUTICS INC (BLSM) | — | 4.5% | +4.5 pts | +3.61M sh | new |
| Reduced | PRAXIS PRECISION MEDICINES I (PRAX) | 11.0% | 9.8% | −1.2 pts | −140K sh | −22% |
| New | ELECTRA THERAPEUTICS INC (ETRA) | — | 2.5% | +2.5 pts | +3.37M sh | new |
| New | ATTOVIA THERAPEUTICS INC (ATTO) | — | 2.1% | +2.1 pts | +1.79M sh | new |
| New | LATIGO BIOTHERAPEUTICS INC (LTGO) | — | 2.0% | +2.0 pts | +1.82M sh | new |
| New | OPUS GENETICS INC (OCUP) | — | 1.8% | +1.8 pts | +5.5M sh | new |
| Reduced | EDGEWISE THERAPEUTICS INC (EWTX) | 5.2% | 5.1% | −0.2 pts | −650K sh | −26% |
| Reduced | ABIVAX SA (ABVX) | 4.6% | 2.8% | −1.8 pts | −250K sh | −37% |
| New | FREENOME INC (FRNM) | — | 1.5% | +1.5 pts | +1.43M sh | new |
| Reduced | DIANTHUS THERAPEUTICS INC (DNTH) | 3.7% | 3.0% | −0.8 pts | −250K sh | −33% |
| Exited | DAMORA THERAPEUTICS INC (GLTO) | 1.3% | — | −1.3 pts | −1M sh | −100% |
| Reduced | BRIDGEBIO PHARMA INC (BBIO) | 2.1% | 1.1% | −1.0 pts | −300K sh | −55% |
| New | ADARX PHARMACEUTICALS INC (ADRX) | — | 1.3% | +1.3 pts | +963K sh | new |
| New | DAMORA THERAPEUTICS INC (DMRA) | — | 1.1% | +1.1 pts | +800K sh | new |
| New | CUE BIOPHARMA INC (CUE) | — | 1.1% | +1.1 pts | +625K sh | new |
| Reduced | TANGO THERAPEUTICS INC (TNGX) | 2.1% | 1.2% | −0.9 pts | −600K sh | −46% |
| Reduced | BIOHAVEN LTD (BHVN) | 2.0% | 1.4% | −0.6 pts | −1.1M sh | −42% |
| Reduced | ERASCA INC (ERAS) | 5.6% | 4.9% | −0.7 pts | −1M sh | −17% |
| Reduced | ROIVANT SCIENCES LTD (ROIV) | 0.9% | 0.2% | −0.6 pts | −375K sh | −79% |
| Reduced | ORUKA THERAPEUTICS INC (ORKA) | 2.6% | 2.2% | −0.4 pts | −133K sh | −25% |
| Reduced | MBX BIOSCIENCES INC (MBX) | 1.6% | 1.5% | −0.1 pts | −175K sh | −32% |
| Reduced | NEWAMSTERDAM PHARMA COMPANY (NAMS) | 0.9% | 0.2% | −0.7 pts | −400K sh | −80% |
| Reduced | PHARVARIS N V (PHVS) | 1.3% | 1.0% | −0.4 pts | −300K sh | −40% |
| New | ACLARIS THERAPEUTICS INC (ACRS) | — | 0.6% | +0.6 pts | +1.75M sh | new |
| Reduced | ALUMIS INC (ALMS) | 4.7% | 1.0% | −3.7 pts | −1.21M sh | −37% |
| Reduced | SPYRE THERAPEUTICS INC (SYRE) | 1.0% | 0.7% | −0.3 pts | −100K sh | −44% |
| Reduced | ASCENDIS PHARMA A/S (ASND) | 0.7% | 0.2% | −0.5 pts | −35,000 sh | −70% |
| Reduced | RAPPORT THERAPEUTICS INC (RAPP) | 5.7% | 5.5% | −0.1 pts | −200K sh | −8% |
| Reduced | INSMED INC (INSM) | 0.4% | 0.2% | −0.3 pts | −55,000 sh | −73% |
| New | INHIBRX BIOSCIENCES INC (INBX) | — | 0.3% | +0.3 pts | +50,000 sh | new |
| Reduced | BRIGHT MINDS BIOSCIENCES INC (DRUG) | 3.2% | 2.7% | −0.6 pts | −100K sh | −11% |
| Reduced | DEFINIUM THERAPEUTICS INC (DFTX) | 1.0% | 0.7% | −0.3 pts | −125K sh | −31% |
| New | JADE BIOSCIENCES INC (JBIO) | — | 0.3% | +0.3 pts | +300K sh | new |
| Reduced | MOONLAKE IMMUNOTHERAPEUTICS (MLTX) | 3.2% | 2.2% | −1.0 pts | −350K sh | −11% |
| Reduced | EYEPOINT INC (EYPT) | 5.1% | 1.3% | −3.9 pts | −1.25M sh | −18% |
| Reduced | TARSUS PHARMACEUTICALS INC (TARS) | 0.3% | 0.3% | −0.1 pts | −50,000 sh | −50% |
| Exited | CRINETICS PHARMACEUTICALS IN (CRNX) | 0.2% | — | −0.2 pts | −125K sh | −100% |
| Reduced | OLEMA PHARMACEUTICALS INC (OLMA) | 1.4% | 1.0% | −0.4 pts | −400K sh | −19% |
| Reduced | ENLIVEN THERAPEUTICS INC (ELVN) | 0.4% | 0.2% | −0.2 pts | −75,000 sh | −50% |
| Reduced | ARCUTIS BIOTHERAPEUTICS INC (ARQT) | 0.2% | 0.1% | −0.1 pts | −125K sh | −71% |
| Increased | AMYLYX PHARMACEUTICALS INC (AMLX) | 0.2% | 0.6% | +0.4 pts | +100K sh | +50% |
| Exited | ALTIMMUNE INC (ALT) | 0.2% | — | −0.2 pts | −1.25M sh | −100% |
| Reduced | RESEARCH ALLIANCE CORP III (RACC) | 0.2% | 0.1% | −0.1 pts | −245K sh | −66% |
| Reduced | ARROWHEAD PHARMACEUTICALS IN (ARWR) | 0.2% | 0.1% | −0.1 pts | −35,000 sh | −70% |
| Reduced | COGENT BIOSCIENCES INC (COGT) | 0.2% | 0.1% | −0.1 pts | −70,000 sh | −70% |
| Reduced | VAXCYTE INC (PCVX) | 0.1% | 0.1% | −0.1 pts | −35,000 sh | −70% |
| Reduced | KAILERA THERAPEUTICS INC (KLRA) | 0.6% | 0.3% | −0.3 pts | −150K sh | −27% |
| New | BRAVEHEART BIO INC (BRVE) | — | 0.1% | +0.1 pts | +70,000 sh | new |
| Reduced | STRUCTURE THERAPEUTICS INC (GPCR) | 0.2% | 0.1% | −0.1 pts | −45,000 sh | −60% |
| Reduced | ODYSSEY THERAPEUTICS INC (ODTX) | 0.2% | 0.2% | 0.0 pts | −50,000 sh | −29% |
The 50 largest of 53 changes, by size of the trade. Full holdings for this quarter.
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 54.8% of the equity book
Changes in the top 10 this quarter: BLSM entered · ANL entered · EYPT left · ALMS left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | PARABILIS MEDICINES INC (PBLS) | 6.5% | 10.0% | |
| 2 | PRAXIS PRECISION MEDICINES I (PRAX) | 11.0% | 9.8% | |
| 3 | RAPPORT THERAPEUTICS INC (RAPP) | 5.7% | 5.5% | |
| 4 | EDGEWISE THERAPEUTICS INC (EWTX) | 5.2% | 5.1% | |
| 5 | BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) | 7.0% | 4.9% | |
| 6 | ERASCA INC (ERAS) | 5.6% | 4.9% | |
| 7 | BLOSSOMHILL THERAPEUTICS INC (BLSM) | 0.0% | 4.5% | Entered the top 10 |
| 8 | ADLAI NORTYE GROUP LTD (ANL) | 2.3% | 4.3% | Entered the top 10 |
| 9 | DIANTHUS THERAPEUTICS INC (DNTH) | 3.7% | 3.0% | |
| 10 | ABIVAX SA (ABVX) | 4.6% | 2.8% | |
| — | EYEPOINT INC (EYPT) | 5.1% | 1.3% | Left the top 10 |
| — | ALUMIS INC (ALMS) | 4.7% | 1.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).